Trial Profile
Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide (Primary)
- Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Lymphoma; Multiple myeloma
- Focus Therapeutic Use
- 16 Dec 2019 Status changed from recruiting to completed.
- 14 Jan 2019 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 14 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.